类风湿关节炎合并新诊断乳腺癌患者中生物制剂改善病情抗风湿药的使用情况
基于CDM、SEER-Medicare与TCR-Medicare三个数据库的回顾性队列研究,纳入2008年起确诊的类风湿关节炎合并乳腺癌成人患者(CDM 1412例,SEER/TCR-Medicare 1439例),描述乳腺癌诊断后三年内生物制剂改善病情抗风湿药(bDMARD)的使用趋势。结果显示诊断后三年内使用率为24.1%(CDM)与26.4%(SEER/TCR-Medicare),约70%患者使用糖皮质激素且无显著时间趋势上升;最强预测因素为乳腺癌前曾使用bDMARD。
要点
- 乳腺癌诊断后三年内bDMARD使用率为24.1%(CDM)与26.4%(SEER/TCR-Medicare)。
- 两队列约70%患者使用糖皮质激素,未见显著时间趋势上升。
- 乳腺癌前曾用bDMARD是最强预测因素(CDM OR 27.15,SEER/TCR OR 18.98)。
核心结论
- 2008年以来,类风湿关节炎合并近期乳腺癌患者中肿瘤坏死因子抑制剂及其他bDMARD的使用未增加,糖皮质激素使用仍较高,乳腺癌前曾用bDMARD是使用的最强预测因素。
研究设计与样本
- 回顾性队列研究,数据来自Optum去标识化Clinformatics® Data Mart数据库(CDM)、SEER-Medicare与德克萨斯州癌症登记-Medicare(TCR-Medicare)数据库,纳入2008年起确诊的类风湿关节炎合并乳腺癌成人患者,CDM 1412例、SEER/TCR-Medicare 1439例。
- 评估乳腺癌诊断后前三年的bDMARD使用趋势,并采用多变量logistic回归分析使用与患者特征的关联。
主要发现
- 乳腺癌诊断前三个月内接受bDMARD者占28.2%(CDM)与26.9%(SEER/TCR-Medicare);诊断后前三年内使用bDMARD者占24.1%(CDM)与26.4%(SEER/TCR-Medicare)。
- 两队列约70%患者接受糖皮质激素,未见显著的时间趋势上升。
- bDMARD使用的最强预测因素为乳腺癌前曾使用(CDM:OR 27.15,95%CI 19.29-38.19;SEER/TCR:OR 18.98,95%CI 13.72-26.26)。
- 在SEER/TCR-Medicare中,与原位或局限性乳腺癌相比,区域性和远处乳腺癌与较低的bDMARD使用相关(OR 0.54,95%CI 0.36-0.82;OR 0.31,95%CI 0.13-0.77)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Biologic disease-modifying antirheumatic drugs (bDMARDs) are immunosuppressants, and there have been concerns that they might impact tumor immunity in patients with cancer with rheumatoid arthritis (RA). The purpose of this study was to describe the utilization trends of bDMARD in patients with RA after breast cancer (BC) diagnosis. METHODS: We performed a retrospective cohort study of adults with RA and BC (2008 onward) from Optum's de-identified Clinformatics® Data Mart Database (CDM); the Surveillance, Epidemiology, and End Results Program (SEER) Medicare; and the Texas Cancer Registry (TCR) Medicare databases. We evaluated bDMARD utilization trends during the first three years after BC. We conducted multivariable logistic regression to evaluate the association of utilization with patient characteristics. RESULTS: A total 1,412 patients were identified in CDM and 1,439 patients in SEER/TCR-Medicare. During the three months before BC diagnosis, 28.2% (CDM) and 26.9% (SEER/TCR-Medicare) patients had received bDMARDs. Within the first three years after diagnosis, 24.1% (CDM) and 26.4% (SEER/TCR-Medicare) were receiving bDMARDs. About 70% of the patients in the two cohorts received glucocorticoids with no significant time trend increases. The largest predictor of bDMARD utilization was prior use before BC (CDM: odds ratio [OR] 27.15, 95% confidence interval [CI] 19.29-38.19; SEER/TCR: OR 18.98, 95% CI 13.72-26.26). Regional and distant BC compared to in situ or localized were also associated with lower bDMARDs utilization in SEER/TCR-Medicare (OR 0.54, 95% CI 0.36-0.82; OR 0.31, 95% CI 0.13-0.77, respectively). CONCLUSION: The utilization of tumor necrosis factor inhibitors and other bDMARDs in patients with RA and recent BC has not increased since 2008. Glucocorticoids utilization remained high. The largest predictor of bDMARD utilization was prior use before BC.
引用
- Ruiz JI, Lei X, Wu CF, et al. Utilization of Biologic Disease-Modifying Antirheumatic Therapy in Patients With Rheumatoid Arthritis and Recently Diagnosed Breast Cancer. Arthritis Care Res (Hoboken). 2024. PMID: 38268474. doi:10.1002/acr.25306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。